Treatment of Early-Stage Hormone Receptor–Positive Breast Cancer

H&O What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR […]

Cyclin-Dependent Kinase 4/6 Inhibition in the Treatment of Hormone Receptor–Positive Breast Cancer

H&O Which CDK4/6 inhibitors are being used to treat advanced and metastatic HR-positive, HER2-negative breast cancer? HR The cyclin-dependent kinase 4/6 (CDK4/6) inhibitors that are […]

Phosphoinositide 3-Kinase Inhibition in the Treatment of Hormone Receptor–Positive Breast Cancer

H&O Which patients are eligible for treatment with alpelisib? HR One of the major advances this year in treating hormone receptor (HR)-positive breast cancer has […]

Highlights in Breast Cancer From the 2019 American Society of Clinical Oncology Annual Meeting

Ribociclib Improves Overall Survival in Hormone Receptor–Positive Breast Cancer The cyclin-dependent kinase 4/6 inhibitor ribociclib (Kisqali, Novartis) improves overall survival (OS) in women with hormone […]

The Dawn of Immunotherapy for Breast Cancer

H&O Why have most of the efforts regarding immunotherapy in breast cancer been focused on triple-negative breast cancer? LE Triple-negative breast cancer (TNBC) is a […]

How We Treat Locally Advanced HER2-Positive Breast Cancer

Overview • Neoadjuvant therapy should be the first choice in patients with HER2-positive locally advanced breast cancer. • Pertuzumab should be added to trastuzumab and […]

Balancing the Risks and Benefits of Extended Adjuvant Endocrine Therapy

H&O What is the standard duration of adjuvant endocrine therapy in patients with hormone receptor–positive breast cancer? KJ Historically, it has been at least 5 […]

Highlights From the 2018 San Antonio Breast Cancer Symposium

T-DM1 Benefits Women With Residual Disease After Neoadjuvant Chemotherapy and Trastuzumab Women who have residual disease after neoadjuvant chemotherapy and trastuzumab for early-stage human epidermal growth […]

Contemporary Management of the Axilla in Breast Cancer

Abstract: The care of patients with breast cancer in the modern era involves a multimodal approach to treating locoregional and distant disease. Recent studies have […]

Update on Managing Brain Metastases in Breast Cancer

H&O How common are brain metastases in breast cancer? NL Among women with metastatic breast cancer, up to 50% of those with human epidermal growth factor […]

Changing Local Therapy in Breast Cancer: Who Needs What, and When?

Abstract: The local therapy of breast cancer continues to evolve toward less surgery. Breast conservation is firmly in place, with recent trends toward decreased rates […]

Highlights in Breast Cancer From the 2018 American Society of Clinical Oncology Annual Meeting

Highlights in Breast Cancer From the 2018 American Society of Clinical Oncology Annual Meeting June 1-5, 2018 • Chicago, Illinois Commentary by Hope S. Rugo, MD […]

Development of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of BRCA-Mutated Breast Cancer

Abstract: The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP […]

How I Treat Breast Cancer With Positive Lymph Nodes

Overview A metastatic workup is useful for patients with clinical stage III disease. Consider neoadjuvant chemotherapy for patients with lymph node–positive disease. Most patients can […]

The Evolution of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer

H&O Could you describe the indications for olaparib that have been added since it was first approved? SD The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza, […]

The Development of Endoxifen for Breast Cancer

H&O Could you please describe how tamoxifen works, and its history as a treatment for breast cancer? MG Tamoxifen is a selective estrogen receptor modulator […]

How to Manage Patients With Moderate-Risk Germline Mutations

H&O Which germline mutations are associated with a high risk for breast cancer? NT Mutations in BRCA1 and BRCA2, TP53, PTEN, CDH1, and STK11 are considered […]

Real-World Use of Scalp Cooling to Reduce Chemotherapy-Related Hair Loss

H&O How long has scalp cooling been in use as a method to reduce hair loss during chemotherapy? HR Scalp cooling involves the use of […]

Highlights in Breast Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

June 2-6, 2017 • Chicago, Illinois Subset of Patients With Heavily Pretreated Metastatic TNBC Respond to Pembrolizumab A subset of patients with heavily pretreated metastatic triple-negative […]

Which Patients With Early-Stage Triple-Negative Breast Cancer Should Receive a Platinum?

H&O What forms of cancer are typically treated with platinum agents? WS Platinum analogues are used to treat a wide range of solid tumors, including […]